Theranostics Market: How Diagnostic and Therapeutic Technologies Are Converging
The global theranostics market was valued at USD 2.36 billion in 2025 and is projected to grow from USD 2.72 billion in 2026 to USD 8.67 billion by 2034, registering a CAGR of 15.5% during 2026–2034. The market is witnessing strong growth due to the rising prevalence of cancer and other chronic diseases, continued advancements in molecular imaging technologies, and the increasing adoption of precision medicine approaches.
Market Overview
The theranostics market is emerging as a transformative area of precision medicine by combining diagnostic imaging with targeted therapy to create a more personalized approach to disease management. The concept traditionally involves using closely matched diagnostic and therapeutic agents that target the same biological marker, allowing clinicians to identify appropriate patients, visualize disease, administer targeted treatment, and monitor therapeutic response.
Theranostics has become particularly significant in oncology and nuclear medicine, where molecular imaging can identify target expression before treatment. Diagnostic radiopharmaceuticals can help determine whether a tumor expresses a specific target, while a therapeutic counterpart can deliver radiation to those same targeted cells. This approach can support patient selection and individualized treatment planning while potentially limiting exposure to healthy tissues.
The growing integration of molecular imaging, radiopharmaceutical development, precision oncology, and personalized medicine is creating a broader clinical ecosystem for theranostics. Recent advances in prostate-specific membrane antigen and somatostatin receptor targeting have demonstrated how theranostic approaches can move from specialized nuclear medicine applications toward increasingly established cancer-care pathways.
Key Market Growth Drivers
• Growing adoption of precision medicine: Healthcare is increasingly moving away from generalized treatment strategies toward approaches that consider the molecular characteristics of individual patients and their diseases. FDA and NIH both identify patient-specific treatment selection as a central objective of precision medicine.
• Expansion of targeted radiopharmaceutical therapy: Increasing clinical use of targeted radionuclide therapies is strengthening the role of theranostics in oncology. Approved therapies targeting PSMA and somatostatin receptors have helped demonstrate the clinical potential of the approach.
• Advances in molecular imaging: PET and SPECT technologies enable clinicians to visualize biological targets and assess radiopharmaceutical distribution, supporting patient selection, treatment planning, and response assessment.
• Rising cancer burden: The need for more selective treatment strategies is encouraging research into therapies that can target specific tumor characteristics rather than relying exclusively on nonspecific systemic approaches.
• Innovation in radionuclides and targeting molecules: Research into alpha emitters, beta emitters, novel ligands, peptides, antibodies, and other targeting vectors is expanding the potential applications of theranostics.
Key Dynamics
• Integration of diagnosis and treatment: Theranostics connects molecular diagnosis with targeted treatment, creating a continuous pathway from target identification to therapeutic intervention and monitoring.
• Personalized dosimetry: Quantitative imaging can help estimate how therapeutic radiopharmaceuticals are distributed within tumors and normal tissues, supporting patient-specific treatment planning.
• Multidisciplinary collaboration: Successful theranostic programs require cooperation among nuclear medicine specialists, oncologists, radiologists, medical physicists, pharmacists, radiochemists, and other healthcare professionals.
• Expansion beyond established indications: Research is investigating new molecular targets, tumor types, radionuclides, and combinations with other systemic therapies.
• Increasing importance of companion diagnostics: Target verification is becoming an essential component of precision treatment because the presence and distribution of a molecular target can influence whether a patient is suitable for a targeted therapy.
Key Companies
Abbott Laboratories
Advanced Accelerator Applications
Astellas Pharma Inc.
Bayer AG
Cardinal Health, Inc.
Curium Pharma
F. Hoffmann-La Roche AG
GE HealthCare Technologies Inc.
Illumina, Inc.
Lantheus Holdings, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Market Challenges and Opportunities
Market Challenges
• Complex infrastructure requirements: Theranostic treatment requires specialized imaging systems, radiopharmaceutical handling capabilities, radiation-safety infrastructure, trained personnel, and appropriate clinical facilities.
• Radiopharmaceutical supply constraints: Many therapeutic radionuclides have specialized production and logistics requirements. Reliable manufacturing, transportation, storage, and timely delivery are essential for clinical programs.
• Regulatory complexity: Theranostic products often involve coordinated development of diagnostic and therapeutic components, creating additional considerations around manufacturing, clinical evidence, quality, and regulatory approval.
• Limited specialized expertise: The multidisciplinary nature of theranostics creates demand for professionals with expertise spanning nuclear medicine, oncology, imaging, radiopharmacy, dosimetry, and radiation safety.
• Treatment access disparities: Advanced theranostic services remain concentrated in healthcare systems with sophisticated nuclear medicine infrastructure, limiting availability in some regions.
Market Opportunities
• New molecular targets: Identification of additional tumor-specific targets can expand theranostics into new cancer indications and patient populations.
• Next-generation radionuclides: Alpha-particle and other emerging radionuclide technologies could provide additional options for treating tumors with highly targeted radiation delivery.
• Combination therapies: Researchers are evaluating radiopharmaceuticals alongside other systemic treatments, potentially creating more comprehensive treatment strategies. The National Cancer Institute is supporting clinical evaluation of novel radiopharmaceutical combinations.
• Artificial intelligence and quantitative imaging: AI-supported image analysis could improve target identification, segmentation, treatment planning, and response assessment.
• Expansion into additional diseases: Although oncology is currently the most prominent application area, the broader theranostic concept may support applications where a measurable biological target can be linked to a corresponding therapeutic intervention.
Market Segmentation
By Product Type Outlook (Revenue – USD Billion, 2021–2034)
Instruments
Reagents
Software
By Application Outlook (Revenue – USD Billion, 2021–2034)
Oncology
Neurology
Cardiology
Infectious Diseases
By Technology Outlook (Revenue – USD Billion, 2021–2034)
Genomics
Proteomics
Metabolomics
Biomarkers
By End User Outlook (Revenue – USD Billion, 2021–2034)
Hospitals
Diagnostic Laboratories
Research Institutes
Future Outlook
The future of the theranostics market is closely linked to the continued evolution of precision oncology and molecular medicine. As researchers identify new biological targets and develop increasingly selective radiopharmaceuticals, the ability to determine which patients are most likely to benefit from a particular therapy will become increasingly important.
The industry is also moving toward more personalized treatment planning. Quantitative imaging and dosimetry can provide information about radiopharmaceutical distribution, helping clinicians assess target uptake and potentially optimize therapeutic exposure.
Another important development is the expansion of theranostic pipelines. Research is progressing toward novel ligands, new radionuclides, additional tumor targets, expanded indications, and combinations with other therapies. The National Cancer Institute has established dedicated infrastructure to support clinical evaluation of novel radiopharmaceutical therapies and combinations.
Overall, theranostics represents a significant shift toward a more targeted and individualized model of healthcare. By connecting molecular diagnosis with targeted therapy, the approach can provide clinicians with information before, during, and after treatment. As imaging technologies, radiopharmaceutical science, artificial intelligence, and precision medicine continue to advance, theranostics is positioned to become an increasingly important component of modern personalized healthcare.
Comments